Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

被引：2
作者：
Revuelta-Herrero, J. L. [1 ]
Gimenez-Manzorro, A. [1 ]
Matilla-Pena, A.
Herranz-Alonso, A. [1 ,2 ]
Sanjurjo-Saez, M. [1 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Pharm Dept, IiSGM, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Gastroenterol Dept, IiSGM, Madrid, Spain
来源：
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2018年 / 43卷 / 06期
关键词：
antiviral agents; drug interaction; hepatitis C; hepatocellular carcinoma; sorafenib; HEPATOCELLULAR-CARCINOMA; EVENTS; HCC;
D O I：
10.1111/jcpt.12727
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
What is known and objective No studies have evaluated the use of sorafenib with the direct-acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV). Case summaryWhat is new and conclusionThree hepatitis C virus genotype 1b-infected patients with well-preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain. The other two patients reported only grade 1 adverse effects. Sustained virologic response at 24weeks was achieved, and no tumour recurrences were found. The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective.
引用
收藏
页码：906 / 909
页数：4
相关论文
共 50 条
  • [21] Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis
    Ascione, Antonio
    De Luca, Massimo
    Melazzini, Mario
    Montilla, Simona
    Trotta, Maria Paola
    Petta, Salvatore
    Puoti, Massimo
    Sangiovanni, Vincenzo
    Messina, Vincenzo
    Bruno, Savino
    Izzi, Antonio
    Villa, Erica
    Aghemo, Alessio
    Zignego, Anna Linda
    Orlandini, Alessandra
    Fontanella, Luca
    Gasbarrini, Antonio
    Marzioni, Marco
    Giannini, Edoardo G.
    Craxi, Antonio
    INFECTION, 2018, 46 (05) : 607 - 615
  • [22] Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong
    Chan, Henry Lik-Yuen
    Tsang, Owen Tak-Yin
    Hui, Yee-Tak
    Fung, James
    Lui, Grace Chung-Yan
    Lai, Ching-Lung
    Wong, Grace Lai-Hung
    Chan, Kam-Hon
    But, David Yiu-Kuen
    Lai, Moon-Sing
    Lao, Wai-Cheung
    Chan, Carmen Ka-Man
    Lam, Yip-Shun
    Seto, Wai-Kay
    Li, Carlton
    Yuen, Man-Fung
    Wong, Vincent Wai-Sun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (06) : 1230 - 1233
  • [23] Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection
    Johnson, Scott J.
    Parise, Helene
    Virabhak, Suchin
    Filipovic, Ivana
    Samp, Jennifer C.
    Misurski, Derek
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 983 - 994
  • [24] Paritaprevir/ritonavir/ombitasvir plus dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report
    Puglisi, G. M.
    Smith, S. M.
    Jankovich, R. D.
    Ashby, C. R.
    Jodlowski, T. Z.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (01) : 115 - 118
  • [25] Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders
    Fuchs, Michael
    Monto, Alexander
    Brau, Norbert
    Charafeddine, Mariem
    Schmidt, Warren
    Kozal, Michael
    Naggie, Susanna
    Cheung, Ramsey
    Schnell, Gretja
    Yu, Yao
    Richards, Kristine
    Mullally, Victoria
    Cohen, Daniel E.
    Toro, Doris
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (12) : 3459 - 3464
  • [26] Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection
    Danis, Nilay
    Toz, Huseyin
    Unal, Nalan
    Yilmaz, Mumtaz
    Turan, Ilker
    Gunsar, Fulya
    Karasu, Zeki
    Ersoz, Galip
    Ozkahya, Mehmet
    Akarca, Ulus Salih
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (08) : 695 - 701
  • [27] Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
    Perello, C.
    Carrion, J. A.
    Ruiz-Antoran, B.
    Crespo, J.
    Turnes, J.
    Llaneras, J.
    Lens, S.
    Delgado, M.
    Garcia-Samaniego, J.
    Garcia-Paredes, F.
    Fernandez, I.
    Morillas, R. M.
    Rincon, D.
    Porres, J. C.
    Prieto, M.
    Lazaro Rios, M.
    Fernandez-Rodriguez, C.
    Hermo, J. A.
    Rodriguez, M.
    Herrero, J. I.
    Ruiz, P.
    Fernandez, J. R.
    Macias, M.
    Pascasio, J. M.
    Moreno, J. M.
    Serra, M. A.
    Arenas, J.
    Real, Y.
    Jorquera, F.
    Calleja, J. L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (03) : 226 - 237
  • [28] Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience
    Degertekin, Bulent
    Demir, Mehmet
    Akarca, Ulus S.
    Kani, Haluk Tarik
    Ucbilek, Enver
    Yildirim, Emre
    Guzelbulut, Fatih
    Balkan, Ayhan
    Vatansever, Sezgin
    Danis, Nilay
    Demircan, Melek
    Soylu, Aliye
    Yaras, Serkan
    Kartal, Aysun
    Kefeli, Ayse
    Gunduz, Feyza
    Yalcin, Kendal
    Erarslan, Elife
    Aladag, Murat
    Harputluoglu, Murat
    Ozakyol, Aysegul
    Temel, Tuncer
    Akarsu, Mesut
    Sumer, Hale
    Akin, Mete
    Albayrak, Bulent
    Sen, Ilker
    Alkim, Huseyin
    Uyanikoglu, Ahmet
    Irak, Kader
    Oztaskin, Sinem
    Ugurlu, Cagri Burak
    Gunes, Sevkican
    Gurel, Selim
    Nuriyev, Kenan
    Inci, Ismail
    Kacar, Sabite
    Dincer, Dinc
    Doganay, Levent
    Gokturk, Huseyin Savas
    Mert, Ali
    Cosar, Arif Mansur
    Dursun, Hakan
    Atalay, Roni
    Akbulut, Sabiye
    Balkan, Yasemin
    Koklu, Hayrettin
    Simsek, Halis
    Ozdogan, Osman
    Coban, Mehmet
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2020, 31 (12) : 883 - 893
  • [29] Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System
    Ioannou, George N.
    Beste, Lauren A.
    Chang, Michael F.
    Green, Pamela K.
    Lowy, Elliott
    Tsui, Judith I.
    Su, Feng
    Berry, Kristin
    GASTROENTEROLOGY, 2016, 151 (03) : 457 - +
  • [30] Successful treatment of HCV-associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin: A case report
    Makara, Mihaly
    Sulyok, Mihaly
    Csacsovszki, Otto
    Sulyok, Zita
    Valyi-Nagy, Istvan
    JOURNAL OF CLINICAL VIROLOGY, 2015, 72 : 66 - 68
12345